JP2022548875A5 - - Google Patents

Info

Publication number
JP2022548875A5
JP2022548875A5 JP2022516404A JP2022516404A JP2022548875A5 JP 2022548875 A5 JP2022548875 A5 JP 2022548875A5 JP 2022516404 A JP2022516404 A JP 2022516404A JP 2022516404 A JP2022516404 A JP 2022516404A JP 2022548875 A5 JP2022548875 A5 JP 2022548875A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
salt
ascorbic acid
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022516404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548875A (ja
JP7762648B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/075767 external-priority patent/WO2021052960A1/en
Publication of JP2022548875A publication Critical patent/JP2022548875A/ja
Publication of JP2022548875A5 publication Critical patent/JP2022548875A5/ja
Priority to JP2025176508A priority Critical patent/JP2026031934A/ja
Application granted granted Critical
Publication of JP7762648B2 publication Critical patent/JP7762648B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022516404A 2019-09-16 2020-09-15 安定した濃縮放射性医薬組成物 Active JP7762648B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025176508A JP2026031934A (ja) 2019-09-16 2025-10-20 安定した濃縮放射性医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19197607 2019-09-16
EP19197607.5 2019-09-16
PCT/EP2020/075767 WO2021052960A1 (en) 2019-09-16 2020-09-15 Stable, concentrated radiopharmaceutical composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025176508A Division JP2026031934A (ja) 2019-09-16 2025-10-20 安定した濃縮放射性医薬組成物

Publications (3)

Publication Number Publication Date
JP2022548875A JP2022548875A (ja) 2022-11-22
JP2022548875A5 true JP2022548875A5 (https=) 2023-09-25
JP7762648B2 JP7762648B2 (ja) 2025-10-30

Family

ID=67981980

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022516404A Active JP7762648B2 (ja) 2019-09-16 2020-09-15 安定した濃縮放射性医薬組成物
JP2025176508A Pending JP2026031934A (ja) 2019-09-16 2025-10-20 安定した濃縮放射性医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025176508A Pending JP2026031934A (ja) 2019-09-16 2025-10-20 安定した濃縮放射性医薬組成物

Country Status (11)

Country Link
US (2) US20220401593A1 (https=)
EP (1) EP4031193A1 (https=)
JP (2) JP7762648B2 (https=)
KR (1) KR20220063218A (https=)
CN (1) CN114728088A (https=)
AR (1) AR119974A1 (https=)
AU (1) AU2020349002B2 (https=)
CA (1) CA3154302A1 (https=)
IL (1) IL291315A (https=)
TW (1) TW202123976A (https=)
WO (1) WO2021052960A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4442285A1 (en) * 2021-11-30 2024-10-09 Nihon Medi-Physics Co., Ltd. Stabilized radiopharmaceutical composition
CN114404618A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其用途
CN114404619A (zh) * 2022-03-28 2022-04-29 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
CN116920129A (zh) * 2022-04-02 2023-10-24 北京先通国际医药科技股份有限公司 放射性药物水溶液及其制备方法和用途
JP2026505341A (ja) 2023-02-08 2026-02-13 ノバルティス アーゲー 神経膠芽腫を治療するための方法
IL322257A (en) 2023-02-23 2025-09-01 Novartis Ag Methods of treating breast cancer
CN121793988A (zh) 2023-09-13 2026-04-03 东丽株式会社 癌的治疗、预防和/或诊断用药物组合物
TW202527951A (zh) 2023-12-15 2025-07-16 瑞士商諾華公司 用於治療乳腺癌的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5139678B2 (ja) * 2003-07-24 2013-02-06 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 安定な放射性医薬品組成物およびその製法
WO2008009444A1 (en) 2006-07-19 2008-01-24 Van Dulmen, Adrianus, A. Use of ethanol for stabilizing a single-vial liquid formulation of a radiolabeled peptide
ES2745635T3 (es) 2012-09-25 2020-03-03 Advanced Accelerator Applications Usa Inc Antagonistas de GRPR para la detección, diagnóstico y tratamiento del cáncer positivo para GRPR

Similar Documents

Publication Publication Date Title
JP2022548875A5 (https=)
US20200222562A1 (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
Roesch et al. The renaissance of the 68Ge/68Ga radionuclide generator initiates new developments in 68Ga radiopharmaceutical chemistry
JP2023552180A5 (https=)
WO2004069285A1 (en) Improved radiometal complex compositions
JP2008195715A5 (https=)
AU2020268836B2 (en) Para-aminohippuric acid (PAH) as a renal protective substance
JP2012533523A5 (https=)
JP2025506001A5 (https=)
JP2022532187A5 (https=)
BR112014003336B1 (pt) processo para a preparação de complexos de 68 ga, kit de reação e frasco para uso no referido processo
CN115702009A (zh) 用于放射性标记psma结合配体的方法及其试剂盒
JP2025510161A5 (https=)
JP2022554186A5 (https=)
AU2010237040B9 (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
WO2025153102A1 (zh) 一种环状多肽化合物及其应用
CN115484991A (zh) 用于放射性标记psma结合配体的方法及其试剂盒
WO2025153103A1 (zh) 一种含氮化合物及其制备方法与用途
TW202602504A (zh) 放射性醫藥化合物之改良配方
RU2021133829A (ru) Парааминогиппуровая кислота (паг), как вещество для защиты почек
WO2025153101A1 (zh) 一种含氮化合物及其制备方法与用途
Abrunhosa et al. Radiopharmaceuticals: Development and Main Applications
JP2005112750A (ja) 腎臓トランスポーターによる薬物動態の制御方法および製剤
HK1167344A (en) Stabilization of radiopharmaceutical compositions using ascorbic acid
HK1167344B (en) Stabilization of radiopharmaceutical compositions using ascorbic acid